lung cancerDays after J&J update, Nanobiotix pauses trading amid €75M stock offeringNanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect. more ➔
Clinical trialsInfex reports Phase IIa win for anti-Pseudomonas antibodyA new monoclonal antibody approach could add an infection-directed option to the changing treatment landscape for non-cystic fibrosis bronchiectasis. more ➔
biotech licensing dealsSERB to pay Hansa €110M upfront for EU rights to kidney transplant drugSERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug. more ➔
obesityHarbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity betHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform. more ➔
Quantum computing$55m financing round for NVisionWith $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s … more ➔
Boehringer IngelheimCooperationMillions for Preclinical Immunology: Boehringer Teams Up with ImmunitasGerman Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the … more ➔
artificial intelligenceIsomorphic Labs raises $2.1B for AI-enabled drug discovery driveIsomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform. more ➔
Venture CapitalInfex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead assetInfex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate. more ➔
obesityEktaH links novel obesity drug to fat loss, muscle retention in early-phase trialEktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year. more ➔
AITolemy Bio raises €1.4m to build AI control panel for cell biologyCambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic pr … more ➔
Boehringer Ingelheim
